Drug Trial Radar · NCT07833839
ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma
Last checked: Nov 19, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
440
Planned (sponsor's estimate)
Start
Oct 2026
Primary completion
Oct 2031
Study completion Dec 2031
Sponsor
- Lead sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,LtdIndustry
- Sponsor type
- Industry
- First posted
- Sep 22, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, controlled, multicenter Phase III study evaluating the efficacy, safety, pharmacokinetics, and immunogenicity of ZG005 combined with the EP regimen (etoposide plus cisplatin) in participants with advanced NEC who are naive to systemic therapy.
Conditions
- Neuroendocrine Carcinomas (NEC)
Interventions
ZG005 for InjectionDrug
Intravenous infusion
Etoposide InjectionDrug
Intravenous infusion
Cisplatin InjectionDrug
Intravenous infusion
ZG005 placebo for injectionDrug
Intravenous infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall survival (OS)Time frame: Up to 48 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.